- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00003917
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth.
PURPOSE: Randomized phase III trial to compare the effectiveness of topotecan given by infusion with that of topotecan given by mouth in treating patients who have small cell lung cancer that has relapsed following previous therapy.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES: I. Compare the response rate, response duration, time to response, time to progression, and survival of patients with relapsed limited or extensive stage small cell lung cancer treated with oral vs intravenous topotecan. II. Compare the qualitative and quantitative toxicities of these treatment regimens in this patient population. III. Compare the quality of life in these patients.
OUTLINE: This is randomized, multicenter study. Patients are stratified according to gender, liver metastases (yes vs no), and duration of response to prior chemotherapy (6 months or less vs greater than 6 months). Patients are randomized to one of two treatment arms. Arm I: Patients receive topotecan IV over 30 minutes on days 1-5. Arm II: Patients receive topotecan orally on days 1-5. Treatment repeats every 3 weeks in the absence of unacceptable toxicity. Patients experiencing complete or partial response continue until progression or for at least 2 courses past maximal response. Patients with stable disease should receive at least 4 courses. Quality of life is assessed Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- University of Alabama Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85012
- Veterans Affairs Medical Center - Phoenix (Hayden)
-
-
California
-
Bakersfield, California, Verenigde Staten, 93309
- Comprehensive Blood and Cancer Center
-
Fountain Valley, California, Verenigde Staten, 92708
- Pacific Coast Hematology/Oncology Medical Group
-
La Jolla, California, Verenigde Staten, 92037
- Scripps Clinic
-
Los Angeles, California, Verenigde Staten, 90073
- Veterans Affairs Medical Center - West Los Angeles
-
Poway, California, Verenigde Staten, 92064
- Southwest Cancer Care
-
Sacramento, California, Verenigde Staten, 95817
- University of California Davis Cancer Center
-
San Diego, California, Verenigde Staten, 92120
- Kaiser Permanente-Southern California Permanente Medical Group
-
San Diego, California, Verenigde Staten, 92121
- Sidney Kimmel Cancer Center
-
-
Colorado
-
Colorado Springs, Colorado, Verenigde Staten, 80909
- Oncology Clinic, P.C.
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- Shands Cancer Center
-
Jacksonville, Florida, Verenigde Staten, 32207
- Baptist Regional Cancer Institute - Jacksonville
-
Miami, Florida, Verenigde Staten, 33176
- Oncology-Hematology Group of South Florida
-
Pensacola, Florida, Verenigde Staten, 32522
- Baptist Hospital- Pensacola
-
Tampa, Florida, Verenigde Staten, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30912-3620
- Medical College of Georgia Hospital and Clinics
-
-
Illinois
-
Evanston, Illinois, Verenigde Staten, 60201
- Evanston Northwestern Health Care
-
Hines, Illinois, Verenigde Staten, 60141
- Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46219
- Oncology and Hematology Associates, Inc.
-
-
Louisiana
-
Lafayette, Louisiana, Verenigde Staten, 70506
- Louisiana Oncology Associates
-
New Orleans, Louisiana, Verenigde Staten, 70121
- Alton Ochsner Medical Foundation Hospital
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Hospital
-
Pontiac, Michigan, Verenigde Staten, 48341-2985
- St. Joseph Mercy Hospital
-
-
Minnesota
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- CCOP - Metro-Minnesota
-
-
Missouri
-
Saint Louis, Missouri, Verenigde Staten, 63141
- St. John's Mercy Medical Center
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Cooper Cancer Institute
-
Livingston, New Jersey, Verenigde Staten, 07039
- St. Barnabas Medical Center
-
Voorhees, New Jersey, Verenigde Staten, 08043
- Cooper Hospital/University Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, Verenigde Staten, 87505
- Santa Fe Hematology/Oncology
-
-
New York
-
Rochester, New York, Verenigde Staten, 14621
- Rochester General Hospital
-
Syracuse, New York, Verenigde Staten, 13210
- State University of New York - Upstate Medical University
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
Winston-Salem, North Carolina, Verenigde Staten, 27103
- Salem Research
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106-5065
- Ireland Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Penn State Geisinger Cancer Center
-
Lemoyne, Pennsylvania, Verenigde Staten, 17043-1440
- Central Pennsylvania Hematology & Medical Oncology Associates, PC
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- University of Pittsburgh Cancer Institute
-
Reading, Pennsylvania, Verenigde Staten, 19612-6052
- Reading Hospital and Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02912
- Brown University Oncology Group
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29605
- Cancer Centers of the Carolinas
-
Spartanburg, South Carolina, Verenigde Staten, 29303
- Spartanburg Regional Healthcare System
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37901
- Baptist Regional Cancer Center - Knoxville
-
Nashville, Tennessee, Verenigde Staten, 37203
- Sarah Cannon-Minnie Pearl Cancer Center
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Texas Cancer Care
-
Galveston, Texas, Verenigde Staten, 77555-0209
- University of Texas Medical Branch
-
Houston, Texas, Verenigde Staten, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
Lubbock, Texas, Verenigde Staten, 79410
- Joe Arrington Cancer Center
-
Temple, Texas, Verenigde Staten, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23502
- Office of Michael E. Lee
-
Richmond, Virginia, Verenigde Staten, 23226
- Hematology & Oncology Associates of Virginia
-
Roanoke, Virginia, Verenigde Staten, 24014
- Oncology and Hematology Associates of Southwest Virginia, Inc.
-
-
Wisconsin
-
Waukesha, Wisconsin, Verenigde Staten, 53188
- Waukesha Memorial Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed limited or extensive stage small cell lung cancer (SCLC) Disease recurring at least 90 days following completion of first line chemotherapy Partial or complete response to first line therapy Must have at least one bidimensionally measurable non CNS lesion May be within a prior radiation port if at least 6 weeks since prior radiotherapy and progressing Brain and/or leptomeningeal metastases allowed if asymptomatic and not requiring corticosteroids
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 2 months Hematopoietic: WBC at least 3,500/mm3 Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL (after transfusion, if needed) Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present) Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present) Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: No active uncontrolled infection No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I low grade prostate cancer No other severe medical conditions that would preclude study or cause exposure to extreme risk or decreased life expectancy No uncontrolled emesis No active peptic ulcer, diabetes mellitus, chronic gastritis, significant ascites, or other gastrointestinal (GI) conditions (e.g., removal of a portion of the stomach or recent GI obstruction) that would alter absorption or GI motility No history of allergic reactions to compounds chemically related to topotecan Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for 3 months prior to, during, and at least 4 weeks after the study
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior immunotherapy No concurrent immunotherapy for SCLC Chemotherapy: See Disease Characteristics No prior topotecan Only one prior chemotherapy regimen allowed No other concurrent chemotherapy for SCLC Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 24 hours since prior radiotherapy No concurrent radiotherapy for SCLC Surgery: At least 4 weeks since prior surgery Other: At least 30 days or five half lives since other prior investigational drugs No prior drugs (e.g., cisapride) that would alter absorption or GI motility No other concurrent investigational therapy for SCLC
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Nathan Levitan, MD, Case Comprehensive Cancer Center
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van de luchtwegen
- Neoplasmata
- Longziekten
- Neoplasmata per site
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Longneoplasmata
- Kleincellig longcarcinoom
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Topoisomeraseremmers
- Topoisomerase I-remmers
- Topotecan
Andere studie-ID-nummers
- SKF1598
- CWRU-SKF-1598
- SB-104864-A/396
- NCI-G99-1524
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Longkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op topotecan hydrochloride
-
Targeted Therapy Technologies, LLCActief, niet wervend
-
The Hospital for Sick ChildrenWerving
-
Hospital JP GarrahanHospital San Juan de Dios, SantiagoActief, niet wervendEenzijdig retinoblastoomArgentinië
-
Gustave Roussy, Cancer Campus, Grand ParisErasmus Medical Center; Catholic University of the Sacred Heart; St. Anna KinderkrebsforschungVoltooidNeuroblastoom | Vaste tumoren | HersentumorsFrankrijk
-
GlaxoSmithKlineVoltooid
-
GlaxoSmithKlineVoltooidEndometriumkanker | Neoplasmata, endometriumVerenigde Staten, Canada, Hongarije
-
Gachon University Gil Medical CenterOnbekendLongkanker | Ongevoelig voor chemotherapieKorea, republiek van
-
GlaxoSmithKlineVoltooidLongkanker, kleine celVerenigde Staten, Nederland
-
GlaxoSmithKlineVoltooidLongkanker, kleine celBulgarije, Hongarije, Russische Federatie, Nederland, Oekraïne, Verenigd Koninkrijk
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)VoltooidEierstokkanker | Eileiderkanker | Primaire peritoneale holtekankerVerenigde Staten